Glycoprotein Non-Metastatic Melanoma Protein B in Cancer Biology
Summary
Glycoprotein non-metastatic melanoma protein B (GPNMB) is a type I transmembrane glycoprotein that is aberrantly overexpressed in a range of malignancies, including breast, melanoma, prostate and lung cancers. Within the tumour microenvironment, GPNMB orchestrates key processes governing tumour progression such as cell adhesion, migration, invasion and immune modulation. Proteolytic shedding of its ectodomain by metalloproteases liberates a soluble fragment that acts in a paracrine manner to recruit endothelial cells and promote angiogenesis. Through interactions with receptors such as integrins and CD44, GPNMB engages downstream signalling cascades—including PI3K/Akt and MEK/ERK—enhancing tumour cell survival, proliferation and metastatic potential. Clinically, elevated GPNMB expression is associated with poor prognosis and resistance to conventional therapies. Consequently, GPNMB has emerged both as a prognostic biomarker and as a promising target for novel interventions, notably antibody-based and bispecific T-cell engaging immunotherapies that exploit its cell-surface localisation to direct tumour cell killing.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Glycoprotein Non-Metastatic Melanoma Protein B in Cancer Biology publication trend
The graph below shows the total number of articles in glycoprotein non-metastatic melanoma protein b in cancer biology across all publications each year (not limited to Nature Index journals).
Technical terms
Ectodomain: The extracellular segment of a transmembrane protein that can be proteolytically cleaved and released to act as a signalling molecule.
Angiogenesis: The process by which new blood vessels form from existing vasculature, essential for supplying nutrients and oxygen to growing tumours.
Matrix metalloproteinase (MMP): A family of zinc-dependent endopeptidases that degrade extracellular matrix components, facilitating tissue remodelling, invasion and metastasis.
Bispecific T-cell engager (BiTE): A recombinant construct designed to bind simultaneously to a tumour-associated antigen and to CD3 on T cells, thereby redirecting cytotoxic T cells to target and kill cancer cells.
References
- ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties. PLOS ONE (2010).
- Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells. Oncotarget (2016).
- Human Antibody VH Domains Targeting GPNMB and VCAM‑1 as Candidate Therapeutics for Cancers. Molecular Pharmaceutics (2023).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.